Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 7:46 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2257–2280 of 3,875 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: fast Clear all

Conditions: Pregnancy Preterm, Neonatal Hypoglycemia, Hyperglycemia Drug Induced
Interventions: Maternal glycemic control; Other
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 86 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2021
U.S. locations: 2
States / cities: Birmingham, Alabama • Chapel Hill, North Carolina

Conditions: Depressive Disorder, Major
Interventions: Rapastinel, Placebo; Drug
Lead sponsor: Naurex, Inc, an affiliate of Allergan plc; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 17
States / cities: Birmingham, Alabama • Garden Grove, California • Glendale, California + 14 more

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Capmatinib; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 373 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 13
States / cities: Long Beach, California • Los Angeles, California • Orange, California + 10 more

Conditions: Suicidal Ideation
Interventions: Ketamine, Midazolam; Drug
Lead sponsor: James Murrough; Other
Eligibility: 18 Years to 80 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy Volunteers, Fasting, Fed
Interventions: Apixaban 5 mg Oral Dissolving Film (TAH3311) and Tablet (Eliquis®); Drug
Lead sponsor: TAHO Pharmaceuticals Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Multiple Myeloma, Low-Grade Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Lymphoplasmacytic Lymphoma, Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia
Interventions: 64Cu-LLP2A, PET/CT; Drug · Device
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Appetitive Behavior
Interventions: High protein ramen, Standard ramen; Other
Lead sponsor: Texas Tech University; Other
Eligibility: 25 Years to 45 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Lubbock, Texas

Conditions: Female Sexual Dysfunction
Interventions: Electrical Stimulation, Smart vibrator; Device
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 85 Years · Female only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Infection, Human Immunodeficiency Virus, HIV Infections
Interventions: GSK2248761 formulation 1, GSK2248761 reference formulation, GSK2248761 formulation 3, GSK2248761 formulation 2 or 4; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Encopresis, ASD
Interventions: Glycerin Suppository, Behavioral strategies; Drug · Behavioral
Lead sponsor: Emory University; Other
Eligibility: 5 Years to 12 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Obesity & Overweight
Interventions: gut-brain axis (GLP-1)-activating food carbohydrate, starch-based placebo control (commercial maltodextrin); Drug · Other
Lead sponsor: Indiana University; Other
Eligibility: 12 Years to 18 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Essential Hypertension
Interventions: perindopril erbumine; Drug
Lead sponsor: Roxane Laboratories; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Healthy
Interventions: Extended Phenytoin Sodium Capsules 100 mg, Dilantin® Kapseals® 100 mg; Drug
Lead sponsor: Mylan Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: HIV Infections
Interventions: ChiCAS; Behavioral
Lead sponsor: Centers for Disease Control and Prevention; Federal
Eligibility: 18 Years and older · Male only
Enrollment: 144 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Cardiogenic Shock
Interventions: Interscalene Block, PECS II Block, Superficial Cervical Plexus Block; Procedure
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 60 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania

Conditions: Healthy
Interventions: Colchicine, Atorvastatin; Drug
Lead sponsor: Mutual Pharmaceutical Company, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Type 1 Diabetes Mellitus
Interventions: Commercial Hylenex® recombinant (hyaluronidase human injection), Precommercial Hylenex recombinant (hyaluronidase human injection), Insulin lispro, Insulin aspart, Insulin glulisine; Drug
Lead sponsor: Halozyme Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 456 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 39
States / cities: Concord, California • Encino, California • Escondido, California + 35 more

Conditions: Sepsis, Septicemia, Respiratory Failure, Hemodynamic Instability, COVID-19, Cardiac Arrest, Clinical Deterioration
Interventions: eCARTv5 clinical deterioration monitoring, Standard of care control; Device · Other
Lead sponsor: AgileMD, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 30,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 3
States / cities: New Haven, Connecticut • Clearwater, Florida • Madison, Wisconsin

Conditions: Substance Use Disorders, HIV
Interventions: Population level patient portal based substance involvement screening, Usual Care Substance Use Involvement Screening; Behavioral
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 900 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Lack of Satiety
Interventions: placebo, digestion-resistant maltodextrin; Other · Dietary Supplement
Lead sponsor: Iowa State University; Other
Eligibility: 18 Years to 62 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Ames, Iowa

Conditions: Influenza, Respiratory Viral Infection
Interventions: Point-of-care molecular testing and treatment of influenza; Combination Product
Lead sponsor: University of Washington; Other
Eligibility: 3 Months and older
Enrollment: 1,618 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 9
States / cities: Burien, Washington • Seattle, Washington

Conditions: Hypertension
Interventions: Salt loading, Hydrochlorothiazide (HCTZ); Procedure · Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 65 Years
Enrollment: 124 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Lancaster, Pennsylvania

Conditions: Opioid Use Disorder
Interventions: EMBED CDS, Nurse prompt to complete COWS, Provider Prompt, Patient facing materials, Optimized EMBED, Name of Intervention; Other
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 1,912 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 3
States / cities: Guilford, Connecticut • New Haven, Connecticut

Conditions: Type 2 Diabetes
Interventions: Exenatide, Glargine, Rapid-acting insulin analogs; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 2
States / cities: Atlanta, Georgia

Search by objective public record fields.

Euglycemia After Antenatal Late Preterm Steroids, the E-ALPS Study

A Study of Rapastinel for Rapid Treatment of Depression and Suicidality in Major Depressive Disorder

Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)

Ketamine For Suicidal Ideation

Comparative Bioavailability Study of TAH3311 5 mg Oral Dissolving Film vs ELIQUIS® 5 mg Tablet in Healthy Volunteers

64Cu-LLP2A for Imaging Hematologic Malignancies

Satiety of High-Protein Ramen Noodles

At-Home Neuromodulation for Female Sexual Dysfunction

A Study to Assess Relative Bioavailability and Food Effect of New Formulations of GSK2248761

Comprehensive Toileting Program

Supplementation of Gut-brain Axis (GLP-1)-Activating Carbohydrates for Increasing Satiety in Adolescents With Obesity

Bioequivalency Study of Perindopril Erbumine 8 mg Tablet Under Fasted Conditions

Steady-State Study of Extended Phenytoin Sodium Capsules 100 mg and Dilantin® Kapseals® 100 mg

HIV Prevention Among Latina Transgender Women Who Have Sex With Men: Evaluation of a Locally Developed Intervention

Awake Axillary Impella 5.5 Placement - A Feasibility Trial

Drug-Drug Interaction Study Between Colchicine and Atorvastatin

CONSISTENT 1: Metabolic and Safety Outcomes of Hylenex Recombinant (Hyaluronidase Human Injection) Preadministered at CSII Infusion Site in Participants With Type 1 Diabetes Mellitus (T1DM)

A Rapid Diagnostic of Risk in Hospitalized Patients Using Machine Learning

Achieving Equity in Patient Outcome Reporting for Timely Assessments of Life With HIV and Substance Use

Fibersol-2 Clinical Trials Related to Appetite

Test-and-treat for Influenza in Homeless Shelters

Salt Loading and Thiazide Intervention Study

Adaptive Decision Support for Addiction Treatment Master

Exenatide Inpatient Trial: A Randomized Controlled Pilot Trial on the Safety and Efficacy of Exenatide (Byetta®) Therapy for the Inpatient Management of Patients With Type 2 Diabetes